DiaCarta Gets $8M For Molecular Diagnostics
Hayward, California- and Shanghai-based DiaCarta, a startup developing molecular diagnostics products, said today that it has raised $8M in a Series A funding round. The funding came from BVCF (BioVeda China Fund). As part of the funding, Weixin Xu of BVCF joins the company's board. DiaCarta is developing molecular diagnostics products aimed at detecting mutations in cervical, oral cancer, and in other areas.
posted on Friday, January 9, 2015 (Link to more information)
Related companies:
DiaCarta
Related stories:
> Two Pore Guys Gains $24.5M For Molecular Diagnostics
> Veracyte Gets $28M In Series C For Molecular Diagnostics Products
> VitaPath Genetics Gets $6M
> Lifecode Raises $20.5M For Molecular Diagnostics
> Pathwork Diagnostics Scores $30M
silicontap.com Home